Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Imunon, Inc.IMNN · Entity 8041 | Chief Medical Officer | December 07, 2023 | December 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Imunon, Inc.
Report date December 07, 2023 · Filed December 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2023-12-07 transaction · row 1
1 source rowRow 1 · 2023-12-07 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents grant of restricted stock, which vests on December 11, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2033-12-11 | Direct | 80,000 |
Reported balance
After 2023-12-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-07 · Grant · Acquired 80,000 · Balance 80,000 F2: Represents grant of stock option, which vests with respect to 25% of the shares on December 11, 2024, and the remaining 75% in equal quarterly installments thereafter such that the stock option will be fully vested and exercisable on the fourth anniversary of December 11, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock, which vests on December 11, 2024.
F2: Represents grant of stock option, which vests with respect to 25% of the shares on December 11, 2024, and the remaining 75% in equal quarterly installments thereafter such that the stock option will be fully vested and exercisable on the fourth anniversary of December 11, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2023 Filed Dec 11, 2023 21:07 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001493152-23-044386 · ownership.xml · derivative · entry 2 Hazard Sebastien · CIK 0002003780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-12-11 F2 · derivative.exercise_date: Represents grant of stock option, which vests with respect to 25% of the shares on December 11, 2024, and the remaining 75% in equal quarterly installments thereafter such that the stock option will be fully vested and exercisable on the fourth anniversary of December 11, 2023. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:07 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-044386 · ownership.xml · nonDerivative · entry 1 Hazard Sebastien · CIK 0002003780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents grant of restricted stock, which vests on December 11, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.